Top Markets
#1 Akedo Akedo +59.54%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.99%
#4 Velvet Velvet +41.93%
#5 Black Phoenix Black Phoenix +34.52%
#6 τemplar τemplar +26.67%
#7 Ribbita by Virtuals Ribbita by Virtuals +18.08%
#8 Bitway Bitway +17.19%
#9 Cap Cap +17.11%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.52%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Classifica tra le azioni #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Prezzo delle azioni
$0.41
Ultima sincronizzazione: 2025-01-23
Capitalizzazione di mercato
$1.08M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia CohBar, Inc. (CWBR)

Categoria

Healthcare
Rapporto P/B per CohBar, Inc. (CWBR)
Rapporto P/B al August 2026 TTM: 0.08
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di CohBar, Inc., il rapporto P/B attuale (TTM) è 0.08. Alla fine del 2021, era pari a 0.91.
Storico del rapporto P/B per CohBar, Inc. da 2011 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 0.08 -75.78%
2022 0.32 -64.70%
2021 0.91 -74.27%
2020 3.54 -57.97%
2019 8.42 17.87%
2018 7.14 -70.78%
2017 24.44 213.13%
2016 7.81 115.36%
2015 3.62 -84.35%
2014 23.15 -103.81%
2013 -607.96 -3,077.68%
2012 20.42 0.00%
2011 0.00 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 7,979.10%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 8,091.35%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 4,589.03%
BE